AMENDED AND RESTATED LICENSE AGREEMENTLicense Agreement • November 10th, 2008 • Oncogenex Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances • British Columbia
SECOND AMENDING AGREEMENTSecond Amending Agreement • November 10th, 2008 • Oncogenex Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances
THE UNIVERSITY OF BRITISH COLUMBIA, a corporation continued under the University Act of British Columbia and having its Industry Liaison offices at #103 – 6190 Agronomy Road, Vancouver, British Columbia, V6T 1Z3
EMPLOYMENT AMENDING AGREEMENTEmployment Amending Agreement • November 10th, 2008 • Oncogenex Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances
ONCOGENEX TECHNOLOGIES INC. a corporation incorporated under the laws of Canada and having an office at Vancouver, British Columbia
EXECUTIVE TERMINATION AGREEMENT AND GENERAL RELEASEExecutive Termination Agreement and General Release • November 10th, 2008 • Oncogenex Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances • Washington
This EXECUTIVE TERMINATION AGREEMENT AND GENERAL RELEASE (“Executive Termination Agreement” or “Agreement”) is entered into between Alan Fuhrman (“Executive”) and Sonus Pharmaceuticals, Inc. (to be renamed “OncoGenex Pharmaceuticals, Inc.”) (referred to herein as “Sonus” or “Employer”).
EXECUTIVE TERMINATION AGREEMENT AND GENERAL RELEASEExecutive Termination Agreement and General Release • November 10th, 2008 • Oncogenex Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances • Washington
This EXECUTIVE TERMINATION AGREEMENT AND GENERAL RELEASE (“Executive Termination Agreement” or “Agreement”) is entered into between Michael A. Martino (“Executive”) and Sonus Pharmaceuticals, Inc. (to be renamed “OncoGenex Pharmaceuticals, Inc.”) (“Sonus” or “Employer”).
SECOND AMENDING AGREEMENT AND CONSENTSecond Amending Agreement and Consent • November 10th, 2008 • Oncogenex Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances
THE UNIVERSITY OF BRITISH COLUMBIA, a corporation continued under the University Act of British Columbia and having its Industry Liaison offices at #103 – 6190 Agronomy Road, Vancouver, British Columbia, V6T 1Z3
SECOND AMENDMENT TOArrangement Agreement • November 10th, 2008 • Oncogenex Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances
This Second Amendment to Arrangement Agreement (this "Amendment") is made and entered into as of August 15, 2008, by and between Sonus Pharmaceuticals, Inc. a Delaware corporation ("Sonus"), and OncoGenex Technologies Inc., a corporation organized pursuant to the Canada Business Corporations Act ("OncoGenex"). Sonus and OncoGenex are sometimes referred to herein as the "Parties."
FIRST AMENDMENT TOArrangement Agreement • November 10th, 2008 • Oncogenex Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances
This First Amendment to Arrangement Agreement (this “Amendment”) is made and entered into as of August 11, 2008, by and between Sonus Pharmaceuticals, Inc. a Delaware corporation (“Sonus”), and OncoGenex Technologies Inc., a corporation organized pursuant to the Canada Business Corporations Act (“OncoGenex”). Sonus and OncoGenex are sometimes referred to herein as the “Parties.”
